Novel Blood Cell Biomarker for Late Onset Alzheimer's Disease (AD)

Tech ID: whe000921



Late onset Alzheimer’s disease (LOAD) is the most common neurodegenerative disorder of aging, affecting 5.4 million patients annually in the US alone. It is a progressive, incurable disease and has remained a diagnostic and therapeutic challenge so far. The initial causal factors of this disease are still unclear and this hampers our ability to develop early and predictive diagnostic methods and preventive therapy of LOAD. With current diagnostic tests limited to diagnose disease only after significant brain damage has already occurred, there is a clear unmet need of a reliable, predictive, and minimally invasive test for early diagnosis of LOAD.


Technology Description

Researchers at the Cedars-Sinai Medical Center (CSMC) have discovered a novel blood cell biomarker for late onset Alzheimer’s disease that could be used to develop a diagnostic test for very early detection of LOAD.  Initially, the researchers developed a novel mouse model that accurately represents human AD pathology with clear mechanistic implications of AD biomarker and treatment development.  Using this mouse model, they observed a new and unforeseen cause of AD in the biomarker, which can be detected within blood vessels from AD patients.  Later, studies on human tissues were conducted for validation in human AD patients.



• Novel blood based biomarker and diagnostic test for effective predictive diagnostics of LOAD 

• Reliable, minimally invasive test



The biomarker can be used to develop a diagnostic test for early accurate diagnosis of LOAD and result in improved patient treatment.


Intellectual Property

US provisional patent application filed.


Patent Information:
For Information, Contact:
Wenyue Du
Associate - IP Management & Licensing
Christopher Wheeler